Source comparison
Thymosin Alpha-1 vs VIP: Research Application Comparison
Before selecting a peptide for immune or inflammation research, assess whether your model measures immune cell populations (flow cytometry, lymphocyte counts) or inflammatory mediators (cytokine ELISAs, histological inflammation scores). This table outlines wh
This comparison does not assign a generated winner or score.
- Before selecting a peptide for immune or inflammation research, assess whether your model measures immune cell populations (flow cytometry, lymphocyte counts) or inflammatory mediators (cytokine ELISAs, histological inflammation scores). This table outlines which peptide aligns with common research endpoints.
- Immune senescence / thymic involution
- Directly enhances thymic output and T-cell maturation; increases CD4+/CD8+ populations
- No direct effect on thymus; does not restore T-cell populations
- Thymosin Alpha-1 is the appropriate choice for restoring adaptive immune capacity in aging or immunocompromised models
- Acute inflammatory response (cytokine storm, sepsis models)
- Indirect effect through Treg modulation; slower onset (days to weeks)
- Direct inhibition of TNF-α, IL-6, IL-12 within hours; acts on effector cells
- VIP is superior for rapid anti-inflammatory intervention in acute models
- Autoimmune disease models (EAE, colitis, arthritis)
- Enhances regulatory T-cell function; reduces autoreactive T-cell expansion
- Inhibits Th1/Th17 differentiation and blocks macrophage activation
- Both peptides show efficacy; VIP acts faster, Thymosin Alpha-1 provides sustained immune regulation
- Neuroprotection and neuroinflammation
- No direct CNS receptor activity; effects mediated through peripheral immune modulation
- VPAC receptors highly expressed in microglia and astrocytes; direct neuroprotective signaling
- VIP is the only option for direct CNS anti-inflammatory and neuroprotective effects
- Pulmonary inflammation (ARDS, asthma models)
- Limited direct pulmonary effect; immune modulation may reduce systemic inflammation
- VPAC1 highly expressed in lung epithelium and smooth muscle; directly reduces airway inflammation
- VIP is the preferred peptide for acute lung injury and airway hyperreactivity models
- Viral infection / antiviral immunity
- Enhances dendritic cell antigen presentation; improves CD8+ T-cell cytotoxic function
- Minimal direct antiviral effect; primarily anti-inflammatory
- Thymosin Alpha-1 supports adaptive antiviral immunity; VIP does not enhance viral clearance